Drug Combination Details
| General Information of the Combination (ID: C92603) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Etoposide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ewing sarcoma
[ICD-11: 2B52]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-673 | CVCL_0080 | Ewing sarcoma | Homo sapiens | ||
| TC-71 | CVCL_2213 | Ewing sarcoma | Homo sapiens | |||
| Experimental
Result(s) |
ES cells showed heterogeneity response to ATO and Eto treatment. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-673 | CVCL_0080 | Ewing sarcoma | Homo sapiens | ||
| RD-ES | CVCL_2169 | Ewing sarcoma | Homo sapiens | |||
| SK-N-MC | CVCL_0530 | Ewing sarcoma | Homo sapiens | |||
| mesenchymal stem cell | Healthy | Homo sapiens | ||||
| Experimental
Result(s) |
Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas. | |||||
